praziquantel has been researched along with Aura in 26 studies
azinox: Russian drug
| Excerpt | Relevance | Reference |
|---|---|---|
| "Baseline and follow-up epidemiological, clinical, radiological and therapeutic data related to 10 inoperable patients with cerebral sparganosis that were treated with repeated courses of high-dose praziquantel therapy, with each course consisting of 25 mg/kg thrice daily for 10 days were assessed, followed by analyses of the prognoses, MRI findings and peripheral eosinophil absolute counts." | 7.91 | Follow-up study of high-dose praziquantel therapy for cerebral sparganosis. ( Ding, HY; Liu, XH; Lv, H; Wang, Z; Wang, ZC; Yang, ZH; Yin, HX; Yu, FX; Zhang, P; Zhang, TT; Zhao, PF; Zou, Y, 2019) |
| "Praziquantel (PZQ) was administered to the patients at their admission to the study." | 5.28 | [Neurocysticercosis and praziquantel: long-term development in 100 patients]. ( Livramento, JA; Machado, LR; Nóbrega, JP; Spina-França, A, 1989) |
| "Praziquantel was ineffective and hazardous, causing some known and some previously unreported responses and reactions." | 5.27 | Disseminated cysticercosis. New observations, including CT scan findings and experience with treatment by praziquantel. ( Bhatt, M; Desai, S; Wadia, N, 1988) |
| "18 patients with partial epilepsy and neurocysticercosis were treated with albendazol or praziquantel and followed from 3 months to 12 years." | 5.09 | Cysticidal therapy: impact on seizure control in epilepsy associated with neurocysticercosis. ( Cardoso, TM; Cendes, F; Guerreiro, CA; Kobayashi, E; Santos, IC, 2000) |
| "Baseline and follow-up epidemiological, clinical, radiological and therapeutic data related to 10 inoperable patients with cerebral sparganosis that were treated with repeated courses of high-dose praziquantel therapy, with each course consisting of 25 mg/kg thrice daily for 10 days were assessed, followed by analyses of the prognoses, MRI findings and peripheral eosinophil absolute counts." | 3.91 | Follow-up study of high-dose praziquantel therapy for cerebral sparganosis. ( Ding, HY; Liu, XH; Lv, H; Wang, Z; Wang, ZC; Yang, ZH; Yin, HX; Yu, FX; Zhang, P; Zhang, TT; Zhao, PF; Zou, Y, 2019) |
| " Lastly, widespread neurocysticercosis may be a concern in mass treatment programs that provide praziquantel (for managing schistosomiasis) or albendazole (for managing intestinal worms or lymphatic filariasis) because these drugs may kill cerebral cysticerci, resulting in severe adverse events." | 3.74 | Could neurocysticercosis be the cause of "onchocerciasis-associated" epileptic seizures? ( Eberhard, M; Habumogisha, P; Katabarwa, M; Lakwo, T; Richards, F, 2008) |
| "Neurocysticercosis is the most important parasitic infection of the nervous system in countries of the third world." | 2.38 | Neurocysticercosis. An introduction with special emphasis on new developments in pharmacotherapy. ( Overbosch, D, 1992) |
| "Cerebral paragonimiasis accounted for 21." | 1.42 | Cerebral paragonimiasis: a retrospective analysis of 27 cases. ( Chen, J; Ju, Y; Xia, Y; You, C, 2015) |
| "Cerebral paragonimiasis can cause epilepsy, especially grand mal seizures." | 1.39 | Cerebral paragonimiasis: a retrospective analysis of 89 cases. ( Chen, J; Chen, Z; Cui, G; Feng, H; Hu, R; Lin, J; Meng, H; Pan, J; Wu, N; Zhu, G; Zou, Y, 2013) |
| "After medical treatment of neurocysticercosis, there is usually remission or marked improvement in the associated seizure disorder." | 1.28 | The course of seizures after treatment for cerebral cysticercosis. ( Sotelo, J; Vazquez, V, 1992) |
| " Since praziquantel, the drug used to treat neurocysticercosis, undergoes extensive liver first-pass metabolism, we carried out a prospective study to verify whether there was a decrease in oral bioavailability induced by carbamazepine and phenytoin." | 1.28 | Phenytoin and carbamazepine decreased oral bioavailability of praziquantel. ( Bittencourt, PR; Diekmann, HW; Fernandes, AG; Gracia, CM; Jung, W; Martins, R, 1992) |
| "Neurocysticercosis is an uncommon, and under-recognized condition in Australia." | 1.28 | Neurocysticercosis: an under-recognized cause of neurological problems. ( Collignon, PJ; Crimmins, D; Danta, G; Dwyer, D, 1990) |
| "Praziquantel (PZQ) was administered to the patients at their admission to the study." | 1.28 | [Neurocysticercosis and praziquantel: long-term development in 100 patients]. ( Livramento, JA; Machado, LR; Nóbrega, JP; Spina-França, A, 1989) |
| "Praziquantel was ineffective and hazardous, causing some known and some previously unreported responses and reactions." | 1.27 | Disseminated cysticercosis. New observations, including CT scan findings and experience with treatment by praziquantel. ( Bhatt, M; Desai, S; Wadia, N, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.54) | 18.7374 |
| 1990's | 13 (50.00) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 6 (23.08) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Takayanagui, OM | 1 |
| Haes, TM | 1 |
| Garcia, HH | 1 |
| Del Brutto, OH | 1 |
| Heller, T | 1 |
| Wallrauch, C | 1 |
| Kaminstein, D | 1 |
| Phiri, S | 1 |
| Zhang, P | 1 |
| Zou, Y | 2 |
| Yu, FX | 1 |
| Wang, Z | 1 |
| Lv, H | 1 |
| Liu, XH | 1 |
| Ding, HY | 1 |
| Zhang, TT | 1 |
| Zhao, PF | 1 |
| Yin, HX | 1 |
| Yang, ZH | 1 |
| Wang, ZC | 1 |
| Xia, Y | 1 |
| Ju, Y | 1 |
| Chen, J | 2 |
| You, C | 1 |
| Chen, Z | 1 |
| Lin, J | 1 |
| Zhu, G | 1 |
| Meng, H | 1 |
| Cui, G | 1 |
| Wu, N | 1 |
| Hu, R | 1 |
| Pan, J | 1 |
| Feng, H | 1 |
| Mahanty, S | 1 |
| Madrid, EM | 1 |
| Nash, TE | 1 |
| Katabarwa, M | 1 |
| Lakwo, T | 1 |
| Habumogisha, P | 1 |
| Richards, F | 1 |
| Eberhard, M | 1 |
| Avodé, DG | 1 |
| Bouteille, B | 1 |
| Avimadje, M | 1 |
| Adjien, C | 1 |
| Monteiro, L | 2 |
| Almeida-Pinto, J | 1 |
| Stocker, A | 1 |
| Sampaio-Silva, M | 1 |
| Brouwer, RE | 1 |
| Thijssen, H | 1 |
| van der Meer, JW | 1 |
| Overbosch, D | 2 |
| Del Giudice, P | 1 |
| Bernard, E | 1 |
| Perrin, C | 1 |
| Marty, P | 1 |
| Le Fichoux, Y | 1 |
| Ortonne, JP | 1 |
| Michiels, JF | 1 |
| Dellamonica, P | 1 |
| Fong, GC | 1 |
| Cheung, RT | 1 |
| Carpio, A | 1 |
| Escobar, A | 1 |
| Hauser, WA | 1 |
| Lopes, J | 1 |
| Martins da Silva, A | 1 |
| Morales, NM | 1 |
| Agapejev, S | 1 |
| Morales, RR | 1 |
| Padula, NA | 1 |
| Lima, MM | 1 |
| Santos, IC | 1 |
| Kobayashi, E | 1 |
| Cardoso, TM | 1 |
| Guerreiro, CA | 1 |
| Cendes, F | 1 |
| Vazquez, V | 1 |
| Sotelo, J | 1 |
| Bittencourt, PR | 1 |
| Gracia, CM | 1 |
| Martins, R | 1 |
| Fernandes, AG | 1 |
| Diekmann, HW | 1 |
| Jung, W | 1 |
| Puri, V | 1 |
| Sharma, DK | 1 |
| Kumar, S | 1 |
| Choudhury, V | 1 |
| Gupta, RK | 1 |
| Khalil, A | 1 |
| Heap, BJ | 1 |
| Crimmins, D | 1 |
| Collignon, PJ | 1 |
| Dwyer, D | 1 |
| Danta, G | 1 |
| Spina-França, A | 1 |
| Nóbrega, JP | 1 |
| Machado, LR | 1 |
| Livramento, JA | 1 |
| Yi, ZS | 1 |
| Wadia, N | 1 |
| Desai, S | 1 |
| Bhatt, M | 1 |
6 reviews available for praziquantel and Aura
| Article | Year |
|---|---|
Update on the diagnosis and management of neurocysticercosis.
Topics: Albendazole; Epilepsy; Humans; Magnetic Resonance Imaging; Neurocysticercosis; Praziquantel | 2022 |
Antiparasitic treatment of neurocysticercosis - The effect of cyst destruction in seizure evolution.
Topics: Albendazole; Anticestodal Agents; Antiparasitic Agents; Brain; Cysts; Epilepsy; Female; Humans; Infl | 2017 |
Active neurocysticercosis, parenchymal and extraparenchymal: a study of 38 patients.
Topics: Adolescent; Adult; Albendazole; Animals; Antibodies, Helminth; Brain Diseases; Cerebrospinal Fluid S | 1993 |
[Subcutaneous cysticercosis].
Topics: Adult; Antiparasitic Agents; Antiplatyhelmintic Agents; Brain Diseases; Cysticercosis; Epilepsy; Hum | 1996 |
Cysticercosis and epilepsy: a critical review.
Topics: Albendazole; Anthelmintics; Antiplatyhelmintic Agents; Brain; Brain Diseases; Clinical Trials as Top | 1998 |
Neurocysticercosis. An introduction with special emphasis on new developments in pharmacotherapy.
Topics: Albendazole; Central Nervous System Diseases; Cimetidine; Cysticercosis; Diagnosis, Differential; Di | 1992 |
1 trial available for praziquantel and Aura
| Article | Year |
|---|---|
Cysticidal therapy: impact on seizure control in epilepsy associated with neurocysticercosis.
Topics: Adult; Aged; Albendazole; Anticestodal Agents; Epilepsy; Follow-Up Studies; Humans; Magnetic Resonan | 2000 |
19 other studies available for praziquantel and Aura
| Article | Year |
|---|---|
Case Report: Cysticercosis: Sonographic Diagnosis of a Treatable Cause of Epilepsy and Skin Nodules.
Topics: Adult; Albendazole; Animals; Brain; Cysticercosis; Epilepsy; Female; Humans; Muscle, Skeletal; Prazi | 2017 |
Follow-up study of high-dose praziquantel therapy for cerebral sparganosis.
Topics: Adolescent; Adult; Animals; Anthelmintics; Antibodies, Helminth; Child; Epilepsy; Female; Follow-Up | 2019 |
Cerebral paragonimiasis: a retrospective analysis of 27 cases.
Topics: Adolescent; Adult; Anthelmintics; Central Nervous System Parasitic Infections; Child; Child, Prescho | 2015 |
Cerebral paragonimiasis: a retrospective analysis of 89 cases.
Topics: Adolescent; Adult; Antiplatyhelmintic Agents; Brain; Brain Diseases; Brain Edema; Cerebral Angiograp | 2013 |
Quantitative screening for anticestode drugs based on changes in baseline enzyme secretion by Taenia crassiceps.
Topics: Alkaline Phosphatase; Animals; Anticestodal Agents; Artemisinins; Artesunate; Benzamides; Epilepsy; | 2013 |
Could neurocysticercosis be the cause of "onchocerciasis-associated" epileptic seizures?
Topics: Albendazole; Animals; Anthelmintics; Epilepsy; Humans; Neurocysticercosis; Onchocerca; Onchocerciasi | 2008 |
[Epilepsy, intracranial hypertension, confusional syndrome and cutaneous cysticercosis. Apropos of 1 case observed in a hospital in Benin].
Topics: Adrenal Cortex Hormones; Benin; Confusion; Cysticercosis; Epilepsy; Humans; Intracranial Pressure; M | 1994 |
[2 patients with neurocysticercosis].
Topics: Adult; Anthelmintics; Brain Diseases; Brain Neoplasms; Cysticercosis; Diagnosis, Differential; Epile | 1995 |
Caution with praziquantel in neurocysticercosis.
Topics: Adult; Antiplatyhelmintic Agents; Central Nervous System Diseases; Cerebral Infarction; Cysticercosi | 1997 |
Relationship between cysticercosis and epilepsy.
Topics: Albendazole; Animals; Anthelmintics; Anticestodal Agents; Drug Administration Schedule; Epilepsy; Hu | 1999 |
Clinical aspects of neurocysticercosis in children.
Topics: Albendazole; Anthelmintics; Antiprotozoal Agents; Brazil; Child; Child, Preschool; Eosinophils; Epil | 2000 |
The course of seizures after treatment for cerebral cysticercosis.
Topics: Adult; Albendazole; Brain; Brain Diseases; Cysticercosis; Epilepsy; Female; Follow-Up Studies; Human | 1992 |
Phenytoin and carbamazepine decreased oral bioavailability of praziquantel.
Topics: Adult; Biological Availability; Carbamazepine; Epilepsy; Female; Humans; Male; Phenytoin; Praziquant | 1992 |
Neurocysticercosis in children.
Topics: Adolescent; Albendazole; Brain Diseases; Child; Child, Preschool; Cysticercosis; Drug Therapy, Combi | 1991 |
Cerebral cysticercosis as a common cause of epilepsy in Gurkhas in Hong Kong.
Topics: Adult; Brain Diseases; Cysticercosis; Enzyme-Linked Immunosorbent Assay; Epilepsy; Hong Kong; Humans | 1990 |
Neurocysticercosis: an under-recognized cause of neurological problems.
Topics: Adolescent; Adult; Aged; Australia; Cysticercosis; Diagnosis, Differential; Emigration and Immigrati | 1990 |
[Neurocysticercosis and praziquantel: long-term development in 100 patients].
Topics: Adolescent; Adult; Aged; Brain Diseases; Child; Child, Preschool; Cysticercosis; Epilepsy; Female; F | 1989 |
[Clinical analysis and follow-up study of 92 cases of cerebral schistosomiasis].
Topics: Adolescent; Adult; Brain Diseases; Brain Neoplasms; Child; Epilepsy; Female; Follow-Up Studies; Huma | 1988 |
Disseminated cysticercosis. New observations, including CT scan findings and experience with treatment by praziquantel.
Topics: Adolescent; Adult; Brain; Carbamazepine; Child; Cysticercosis; Dexamethasone; Drug Therapy, Combinat | 1988 |